KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-cash Items: 2011-2024

Historic Non-cash Items for Sarepta Therapeutics (SRPT) over the last 3 years, with Dec 2024 value amounting to $6.3 million.

  • Sarepta Therapeutics' Non-cash Items fell 97.82% to $6.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.3 million, marking a year-over-year decrease of 97.82%. This contributed to the annual value of $425.0 million for FY2024, which is 47.52% up from last year.
  • According to the latest figures from Q4 2024, Sarepta Therapeutics' Non-cash Items is $6.3 million, which was down 97.82% from $288.1 million recorded in Q4 2023.
  • Sarepta Therapeutics' Non-cash Items' 5-year high stood at $557.9 million during Q4 2022, with a 5-year trough of $2.0 million in Q4 2020.
  • Moreover, its 3-year median value for Non-cash Items was $288.1 million (2023), whereas its average is $284.1 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Non-cash Items surged by 12,198.98% in 2021, and later tumbled by 97.82% in 2024.
  • Sarepta Therapeutics' Non-cash Items (Quarterly) stood at $2.0 million in 2020, then skyrocketed by 12,198.98% to $248.5 million in 2021, then spiked by 124.54% to $557.9 million in 2022, then plummeted by 48.36% to $288.1 million in 2023, then tumbled by 97.82% to $6.3 million in 2024.
  • Its Non-cash Items was $6.3 million in Q4 2024, compared to $288.1 million in Q4 2023 and $557.9 million in Q4 2022.